November 18, 2016 - By Louis Casey · 0 Comments
CareDx (NASDAQ:CDNA) institutional sentiment increased to 1.71 in 2016 Q2. Its up 0.14, from 1.57 in 2016Q1. The ratio improved, as 11 institutional investors opened new or increased stock positions, while 7 reduced and sold their holdings in CareDx. The institutional investors in our partner’s database reported: 5.81 million shares, up from 4.90 million shares in 2016Q1. Also, the number of institutional investors holding CareDx in their top 10 stock positions increased from 0 to 1 for an increase of 1. Sold All: 1 Reduced: 6 Increased: 7 New Position: 4.
CareDx, Inc. is a molecular diagnostics company. The company has a market cap of $57.64 million. The Firm is focused on the discovery, development and commercialization of clinically differentiated diagnostic surveillance solutions for transplant patients. It currently has negative earnings. The Company’s commercialized testing solution, the AlloMap heart transplant molecular test , is a gene expression test that helps clinicians monitor and identify heart transplant recipients with stable graft function having a low probability of moderate/severe acute cellular rejection.
About 700 shares traded hands. CareDx Inc (NASDAQ:CDNA) has declined 25.29% since April 18, 2016 and is downtrending. It has underperformed by 29.72% the S&P500.
According to Zacks Investment Research, “CareDx, Inc. is a commercial stage company. It develops, markets, and delivers a diagnostic surveillance solution for heart transplant recipients. The Company provides AlloMap, a noninvasive blood test used to aid in the identification of heart transplant recipients. It is also pursuing other areas of transplant surveillance, such as the use of cell-free DNA (cfDNA) as a biomarker for rejection. CareDx, Inc. is based in Brisbane, California.”
Paragon Associates & Paragon Associates Ii Joint Venture holds 4.95% of its portfolio in CareDx Inc for 1.17 million shares. Gagnon Advisors Llc owns 952,464 shares or 3.54% of their US portfolio. Moreover, Gagnon Securities Llc has 2.76% invested in the company for 1.34 million shares. The California-based Acuta Capital Partners Llc has invested 0.13% in the stock. Tpg Group Holdings (Sbs) Advisors Inc., a Texas-based fund reported 1.08 million shares.#img1#
Insider Transactions: Since January 1, 0001, the stock had 3 insider buys, and 0 insider sales for $794,511 net activity.
Ratings analysis reveals 67% of CareDx’s analysts are positive. Out of 3 Wall Street analysts rating CareDx, 2 give it “Buy”, 0 “Sell” rating, while 1 recommend “Hold”. The lowest target is $8 while the high is $13. The stock’s average target of $10.50 is 213.43% above today’s ($3.35) share price. CDNA was included in 4 notes of analysts from September 25, 2015. The firm earned “Buy” rating on Friday, September 25 by Craig Hallum. The stock has “Market Perform” rating given by Raymond James on Monday, September 28. Mizuho maintained CareDx Inc (NASDAQ:CDNA) on Tuesday, June 14 with “Buy” rating.
CareDx, Inc., incorporated on December 21, 1998, is a molecular diagnostics company. The Firm is focused on the discovery, development and commercialization of clinically differentiated diagnostic surveillance solutions for transplant patients. The Company’s commercialized testing solution, the AlloMap heart transplant molecular test (AlloMap) is a gene expression test that helps clinicians monitor and identify heart transplant recipients with stable graft function having a low probability of moderate/severe acute cellular rejection. AlloMap is a non-invasive method recommended in the International Society for Heart and Lung Transplantation (ISHLT) patient care guidelines for surveillance of heart transplant rejection in patients 15 years of age or older.
Another recent and important CareDx Inc (NASDAQ:CDNA) news was published by Prnewswire.com which published an article titled: “Heart Transplant Patients Warn That CMS Decision Could Deprive Them Of Needed Care” on October 26, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Louis Casey